Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Cabazitaxel significantly improved radiographic progression-free survival and overall survival in the CARD study. The study involved 62 clinical sites across 13 European countries. Patients with metastatic castration-resistant prostate cancer were treated with docetaxel and an androgen signaling-targeted inhibitor. 255 patients were randomly assigned to cabazitaxel or abiraterone or enzalutamide. The Median follow-up was 9 months.
